Immunosuppression-free transplantation through placental mimicry
通过胎盘拟态进行无免疫抑制移植
基本信息
- 批准号:10244763
- 负责人:
- 金额:$ 141.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-14 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AllogenicAntigen-Presenting CellsAntigensAreaCell TherapyCell TransplantationCellsChronicClinicalConceptusDevelopmentEngineeringFetusGeneral PopulationGoalsGraft SurvivalHomologous TransplantationHydrogelsImmune ToleranceImmune responseImmunologyImmunosuppressionIn VitroInfectionLeadMaintenanceMalignant NeoplasmsMesenchymal Stem CellsMethodsMissionMothersOrganOrganoidsPhenotypePhysiologicalPlacentaPregnancyPublic HealthRegimenRegulatory T-LymphocyteResearchRiskRoleTissue TransplantationTissuesTransplant RecipientsTransplantationTransplantation ImmunologyUnited States National Institutes of HealthVaccinesbaseexhaustimmunoregulationimplantationimproved outcomein vivomethod developmentmimicryorganoid transplantationside effecttrophoblast
项目摘要
Project Summary/Abstract
The ultimate goal in clinical transplantation is robust and specific host immunological tolerance toward
transplanted allogeneic tissue and cells. While systemic immunosuppression regimens have saved lives by
enabling long-term allogeneic graft survival, they come with a host of potentially severe side effects, including
infections and malignancies. The development of a method to induce donor-specific, localized tolerance toward
allogeneic grafts, and thereby eliminate the need for chronic systemic immunosuppression, would dramatically
reduce the risks associated with cell and tissue transplantation.
Typical tolerogenic immunomodulatory approaches are systemic, potentially resulting in off-target and
detrimental effects. Many groups have turned toward local delivery or presentation of immunomodulatory factors,
which can eliminate systemic and off-target effects, but have limited opportunity for renewal when exhausted,
resulting in a transient treatment. One approach to achieve more persistent localized immunomodulation
includes the use of tolerogenic cells, such as T regulatory cells, tolerized mesenchymal stem cells or tolerized
antigen presenting cells. However, while these cells can be influenced to take on a tolerogenic phenotype in
vitro, it is unclear whether, or for how long, these manipulated cells maintain this phenotype in vivo. An alternative
strategy would be the use of professional tolerogenic cells, such as placenta-derived trophoblasts, wherein their
primary physiological role is sustained and persistent maintenance of tolerance toward allogeneic tissue.
Our research approaches immunological tolerance from the perspective of the only physiologically natural
scenario of allogeneic tissue tolerance, placental pregnancy. In placental pregnancy, semi-allogeneic and fully
allogeneic conceptus are protected from immune response by the placenta, a fetus-derived organ consisting of
various types of trophoblasts which physically isolate the fetus from the mother. We aim to probe and exploit the
tolerogenic immunomodulatory mechanisms of trophoblasts and their capacity to induce tolerance in allogeneic
graft transplantation through three main projects: (1) develop artificial placenta organoids using tunable hydrogel
matrices to direct trophoblast differentiation and explore their immunomodulatory mechanisms in vitro; (2)
engineer a safe and translatable method of artificial placenta organoid transplantation for tolerogenic cell therapy;
(3) develop a tolerance-inducing vaccine via implantation of artificial placenta organoids for antigen-specific
tolerance against allogeneic grafts. The use of placenta-based mechanisms to induce tolerance toward
allogeneic grafts is a drastically understudied area of immunology, and presents an opportunity to widen and
enrich the broader research areas of transplantation and transplantation immunology.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jessica Diane Weaver其他文献
Jessica Diane Weaver的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jessica Diane Weaver', 18)}}的其他基金
Immunosuppression-free islet transplantation via localized immunomodulatory exosome tethering
通过局部免疫调节外泌体束缚进行无免疫抑制的胰岛移植
- 批准号:
10610867 - 财政年份:2022
- 资助金额:
$ 141.3万 - 项目类别:
Immunosuppression-free islet transplantation via localized immunomodulatory exosome tethering
通过局部免疫调节外泌体束缚进行无免疫抑制的胰岛移植
- 批准号:
10348870 - 财政年份:2022
- 资助金额:
$ 141.3万 - 项目类别:
相似海外基金
Tri-Signal Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的三信号人工抗原呈递细胞
- 批准号:
10751133 - 财政年份:2023
- 资助金额:
$ 141.3万 - 项目类别:
Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的微流控精密工程人工抗原呈递细胞
- 批准号:
10696138 - 财政年份:2022
- 资助金额:
$ 141.3万 - 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
- 批准号:
10663066 - 财政年份:2022
- 资助金额:
$ 141.3万 - 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
- 批准号:
10537159 - 财政年份:2022
- 资助金额:
$ 141.3万 - 项目类别:
Analysis of the function of antigen-presenting cells present in the stroma of colorectal cancer and the intracellular microbiome
结直肠癌基质中抗原呈递细胞和细胞内微生物组的功能分析
- 批准号:
21K08723 - 财政年份:2021
- 资助金额:
$ 141.3万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
- 批准号:
10156950 - 财政年份:2021
- 资助金额:
$ 141.3万 - 项目类别:
The role of CX3CR1+ antigen presenting cells in T cell selection and central tolerance"
CX3CR1抗原呈递细胞在T细胞选择和中枢耐受中的作用"
- 批准号:
10631854 - 财政年份:2021
- 资助金额:
$ 141.3万 - 项目类别:
Reprogramming Cancer Cells into Antigen Presenting Cells: Cancer Vaccination with mRNA Enabled by Charge-Altering Releasable Transporters
将癌细胞重编程为抗原呈递细胞:通过改变电荷的可释放转运蛋白实现 mRNA 的癌症疫苗接种
- 批准号:
10153927 - 财政年份:2021
- 资助金额:
$ 141.3万 - 项目类别:
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
- 批准号:
10331830 - 财政年份:2021
- 资助金额:
$ 141.3万 - 项目类别:
Analysis on detrimental interplay between pathogenic helper T cells, inflammatory antigen-presenting cells and disease-associated microglia in chronic pathogenesis of multiple sclerosis
多发性硬化症慢性发病机制中致病性辅助 T 细胞、炎症抗原呈递细胞和疾病相关小胶质细胞之间的有害相互作用分析
- 批准号:
20K16294 - 财政年份:2020
- 资助金额:
$ 141.3万 - 项目类别:
Grant-in-Aid for Early-Career Scientists